Sugi Predict

Sugi Predict / Targets / GCK

GCK

Hexokinase-4 · P35557 · GCK on Sugi Atlas →

51,227 patent compounds predicted against GCK, 26,120 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16509 SCHEMBL16509 1.00 20/20
SCHEMBL16608 SCHEMBL16608 0.80 20/20
SCHEMBL17469 SCHEMBL17469 0.79 20/20
SCHEMBL16482 SCHEMBL16482 0.75 20/20
SCHEMBL15962 SCHEMBL15962 0.69 20/20
SCHEMBL16575 SCHEMBL16575 0.68 20/20
SCHEMBL15742 SCHEMBL15742 0.67 20/20
SCHEMBL17573 SCHEMBL17573 0.57 20/20
SCHEMBL16960 SCHEMBL16960 0.56 20/20
SCHEMBL16506 SCHEMBL16506 0.52 20/20
SCHEMBL17333 SCHEMBL17333 1.00 19/20
SCHEMBL16852 SCHEMBL16852 0.73 19/20
SCHEMBL16019 SCHEMBL16019 1.00 18/20
SCHEMBL16365 SCHEMBL16365 0.76 18/20
SCHEMBL16831 SCHEMBL16831 0.72 18/20
SCHEMBL17297 SCHEMBL17297 0.53 18/20
SCHEMBL17405 SCHEMBL17405 0.50 18/20
SCHEMBL15911 SCHEMBL15911 0.49 18/20
SCHEMBL16804 SCHEMBL16804 0.49 18/20
SCHEMBL15921 SCHEMBL15921 0.55 17/20

Clinical trials — most relevant to GCK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation PHASE4WITHDRAWN
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes PHASE4COMPLETED
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity PHASE4COMPLETED
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
A Multi-center 12-week Study of HMS5552 in T2DM PHASE2COMPLETED
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC PHASE2UNKNOWN
Ketohexokinase Inhibition in NAFLD PHASE2COMPLETED
Add Glucokinase Activator to Target A1c PHASE2COMPLETED
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency PHASE2UNKNOWN
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride PHASE1COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus PHASE1COMPLETED
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2) PHASE1COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors PHASE1COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer nanUNKNOWN
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism nanUNKNOWN
Effect of Acute Fructose Load in Human nanCOMPLETED
Early Versus Late FDG-PET/CT in Bladder Cancer nanCOMPLETED
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology nanCOMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging nanCOMPLETED
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours nanRECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Fructose and Glucose and TAS1R2 in Type 1 Diabetes nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GCK binder may also engage these)

ProteinNameSimilarity
P52792 — 1.000 P52792 →
P17712 — 1.000 P17712 →
P93834 — 0.999 P93834 →
Q9SQ76 — 0.998 Q9SQ76 →
Q42525 — 0.997 Q42525 →
Q9SEK2 — 0.997 Q9SEK2 →
P80581 — 0.996 P80581 →
Q9FZG4 — 0.996 Q9FZG4 →
Q1WM16 — 0.996 Q1WM16 →
Q26609 — 0.995 Q26609 →
Q2KNB7 — 0.995 Q2KNB7 →
HK1 Hexokinase-1 0.994 landscape →
Q9SEK3 — 0.994 Q9SEK3 →
Q969A8 — 0.993 Q969A8 →
Q5RC71 — 0.993 Q5RC71 →
Q5W676 — 0.993 Q5W676 →
Q9NFT7 — 0.992 Q9NFT7 →
Q9LPS1 — 0.992 Q9LPS1 →
Q6Q8A5 — 0.992 Q6Q8A5 →
O64390 — 0.992 O64390 →
P50521 — 0.992 P50521 →
Q8LQ68 — 0.992 Q8LQ68 →
Q8R2W9 — 0.991 Q8R2W9 →
P27881 — 0.991 P27881 →
Q2KNB9 — 0.991 Q2KNB9 →
Q1WM15 — 0.991 Q1WM15 →
P05708 — 0.990 P05708 →
P17710 — 0.990 P17710 →
A2PYL7 — 0.990 A2PYL7 →
P17709 — 0.989 P17709 →